Publications

Drug delivery

Local application of otoprotective compounds other than sodium thiosulfate to prevent cisplatin-induced hearing loss: a systematic review.

31-12-2026

Cancer chemotherapy and pharmacology

Dosing challenges for chemotherapy and immunotherapy in congenital achondroplasia: a case report and literature review.

03-08-2026

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery

Prestin as a potential biomarker for cochlear injury: Current evidence and future directions.

01-08-2026

Tumori

Optimising combination therapy for paediatric, adolescent and young adult patients with non-rhabdomyosarcoma soft tissue sarcomas: The OCTOPUS platform trial.

30-07-2026

Acta oncologica (Stockholm, Sweden)

The impact of pazopanib and extremity radiotherapy on transaminase elevations in soft tissue sarcoma.

28-07-2026

Clinical pharmacokinetics

Population Pharmacokinetics of Bosutinib in Children with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Based on a Phase I Dose-Finding Trial (ITCC-054/COG AAML1921) and Pediatric Recommended Phase II Dosage Evaluation.

27-07-2026

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Brief report: Reducing Lorlatinib-related Adverse Events by establishing the Optimal Exposure-Toxicity Threshold in Patients with NSCLC.

16-07-2026

The Lancet. Oncology

Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.

01-07-2026

Ear and hearing

Avoiding Cisplatin-Related Hearing Loss, Including Implementing Sodium Thiosulfate as Otoprotectant Into Daily Pediatric Clinical Practice: Proceedings Based on Evidence and Expert Opinion From the Ototoxicity Taskforce of the SIOP Supportive Care Network.

26-06-2026

European journal of cancer (Oxford, England : 1990)

The SHERPA trial: A phase I study combining SHP2 inhibitor RMC-4630 and ERK inhibitor LY3214996 in patients with KRAS-mutant pancreatic, non-small cell lung and colorectal cancer.

18-06-2026

British journal of clinical pharmacology

Clinical response to capecitabine in a DPYD*2A homozygous patient: Case report and therapeutic guidance.

01-06-2026

British journal of clinical pharmacology

Population pharmacokinetics and dose-response relationships of mitoxantrone in children with acute myeloid leukaemia.

01-06-2026

British journal of cancer

Safety and efficacy of lapatinib, binimetinib, and vinorelbine for RAS mutant metastatic colorectal cancer: results of the RASTRIC Phase I/II trial.

01-06-2026

Cancer communications (London, England)

Sex Impacts Progression-Free Survival of Alectinib through Drug Exposure in Patients with ALK-Positive Non-Small Cell Lung Cancer.

25-05-2026

Cancer chemotherapy and pharmacology

Transfer of trastuzumab and pertuzumab into human breast milk: a case report.

20-05-2026

Clinical pharmacokinetics

Exposure-Response Relationships of Antibody Drug Conjugates in Solid Tumours.

01-05-2026

Pharmacogenomics

Acute hemolytic anemia and methemoglobinemia in a pediatric oncology patient with G6PD deficiency: a case report.

13-04-2026

Clinical and translational science

Analytical Validation of an Annotation Tool for WGS-Based Pharmacogenomics: Preparing for Clinical Implementation in Pediatric Oncology.

01-04-2026

Clinical pharmacology and therapeutics

Reducing the Burden of Interaction Studies in Cancer Patients Using a Stable Isotopically Labeled Microtracer: A Proof-of-Concept Study with Alectinib.

01-03-2026

CPT: pharmacometrics & systems pharmacology

Semi-Physiological Population Pharmacokinetic Modeling of Oral and Intravenous Paracetamol to Quantify Presystemic Metabolism and Enterohepatic Recirculation.

01-03-2026

Clinical pharmacokinetics

Population Pharmacokinetics of Total and Protein-Unbound Prednisolone in Children with Immune-Mediated and Systemic Inflammatory Diseases.

01-02-2026

Biomedical chromatography : BMC

An Overview of Liquid Chromatography-Mass Spectrometry (LC-MS) Methods for the Quantification of Antibody-Drug Conjugates.

01-02-2026

Cancer chemotherapy and pharmacology

Selpercatinib-induced renal tubular damage resulting in symptomatic hyponatremia and polyuria: a case report.

04-01-2026

Journal of pharmaceutical and biomedical analysis

LC-MS/MS method development and validation for novel targeted anticancer therapies adagrasib, capmatinib, ensartinib, entrectinib, larotrectinib, lorlatinib, pralsetinib, selpercatinib and sotorasib.

15-12-2025

Therapeutic drug monitoring

Therapeutic Drug Monitoring of Oral Targeted Anticancer Drugs: Achievements, Experiences, Challenges, and the Path Forward.

01-12-2025

Clinical pharmacokinetics

Importance of Lysosomal Trapping and Plasmodium Parasite Infection on the Pharmacokinetics of Pyronaridine: A Physiologically Based Pharmacokinetic Model-Based Study.

01-12-2025

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Prolonged in-use physicochemical and biological stability of nivolumab and pembrolizumab diluted in saline infusion bags and in partially used medication vials.

01-12-2025

Toxicology reports

Accidental tamoxifen ingestion in a two-year-old child without major immediate symptoms: Case report.

01-12-2025

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Measurement of Tralokinumab Concentrations in Serum and Tear Fluid of Atopic Dermatitis Patients and the Relationship With Treatment Response and Ocular Surface Disease.

01-11-2025

British journal of clinical pharmacology

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia-A comprehensive review.

26-10-2025

Therapeutic drug monitoring

Stabilization of Abiraterone in Human Plasma Using the Esterase Inhibitor Bis(4-nitrophenyl) Phosphate.

01-10-2025

Clinical pharmacology and therapeutics

Implementing Pre-Emptive Pharmacogenetics: Impact of Early Pharmacogenetic Screening in a Pediatric Oncology Cohort of 1,151 Subjects.

01-08-2025

Biomedical chromatography : BMC

Validated LC-MS/MS Method for Quantifying the Antiparasitic Nitroimidazole DNDI-0690 in Preclinical Target Site PK/PD Studies.

01-08-2025

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Quantitative analysis of DNDI-6174 using UPLC-MS/MS: A preclinical target site pharmacokinetic study.

01-08-2025

Contemporary clinical trials communications

Pharmacokinetic boosting of olaparib: Study protocol of a multicentre, open-label, randomised, non-inferiority trial (PROACTIVE-B).

01-06-2025

Cancer reports (Hoboken, N.J.)

Imatinib Desensitization After a Type IV Hypersensitivity Reaction in a Gastrointestinal Stromal Tumor Patient-A Case Report.

01-06-2025

Blood advances

Improved survival with model-based dosing of antithymocyte globulin in pediatric hematopoietic cell transplantation.

13-05-2025

European journal of cancer (Oxford, England : 1990)

Added prognostic value of circulating tumor cell numbers in CSF of patients with leptomeningeal metastasis from epithelial tumors.

02-05-2025

British journal of cancer

Feasibility and efficacy of therapeutic drug monitoring of abiraterone in metastatic castration resistant prostate cancer patients.

01-04-2025

ESMO open

Palbociclib exposure in relation to efficacy and toxicity in patients with advanced breast cancer.

01-03-2025

Drug discovery today

The feasibility of using real world data as external control arms in oncology trials.

01-03-2025

Bone marrow transplantation

Evaluation of standard fludarabine dosing and corresponding exposures in infants and young children undergoing hematopoietic cell transplantation.

01-02-2025

Breast cancer research and treatment

Treatment sequences and survival outcomes in advanced HR + HER2- breast cancer patients: a real-world cohort.

01-02-2025

Cancer chemotherapy and pharmacology

Pharmacokinetic exposure and treatment outcomes of lenvatinib in patients with renal cell carcinoma and differentiated thyroid carcinoma.

17-01-2025

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Development and validation of ultra-performance liquid chromatography tandem mass spectrometry methods for the quantitative analysis of the antiparasitic drug DNDI-6148 in human plasma and various mouse biomatrices.

01-01-2025

Clinical pharmacokinetics

A Population Pharmacokinetic Study to Evaluate Doxorubicin Exposure Across All Age Groups.

01-12-2024

Clinical pharmacology and therapeutics

Therapeutic Drug Monitoring of Oral Oncology Drugs: Finding the Right Nails.

01-09-2024

British journal of cancer

Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology - an analysis of the closed cohorts of a multicentre prospective study.

01-09-2024

Cancer chemotherapy and pharmacology

A joint model of longitudinal pharmacokinetic and time-to-event data to study exposure-response relationships: a proof-of-concept study with alectinib.

01-09-2024

Blood neoplasia

Effect of clofarabine and fludarabine exposure on outcome after pediatric allogeneic hematopoietic cell transplantation.

01-09-2024

Local application of otoprotective compounds other than sodium thiosulfate to prevent cisplatin-induced hearing loss: a systematic review.

Dosing challenges for chemotherapy and immunotherapy in congenital achondroplasia: a case report and literature review.

Prestin as a potential biomarker for cochlear injury: Current evidence and future directions.

Optimising combination therapy for paediatric, adolescent and young adult patients with non-rhabdomyosarcoma soft tissue sarcomas: The OCTOPUS platform trial.

The impact of pazopanib and extremity radiotherapy on transaminase elevations in soft tissue sarcoma.

Population Pharmacokinetics of Bosutinib in Children with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Based on a Phase I Dose-Finding Trial (ITCC-054/COG AAML1921) and Pediatric Recommended Phase II Dosage Evaluation.

Brief report: Reducing Lorlatinib-related Adverse Events by establishing the Optimal Exposure-Toxicity Threshold in Patients with NSCLC.

Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.

Avoiding Cisplatin-Related Hearing Loss, Including Implementing Sodium Thiosulfate as Otoprotectant Into Daily Pediatric Clinical Practice: Proceedings Based on Evidence and Expert Opinion From the Ototoxicity Taskforce of the SIOP Supportive Care Network.

The SHERPA trial: A phase I study combining SHP2 inhibitor RMC-4630 and ERK inhibitor LY3214996 in patients with KRAS-mutant pancreatic, non-small cell lung and colorectal cancer.

Clinical response to capecitabine in a DPYD*2A homozygous patient: Case report and therapeutic guidance.

Population pharmacokinetics and dose-response relationships of mitoxantrone in children with acute myeloid leukaemia.

Safety and efficacy of lapatinib, binimetinib, and vinorelbine for RAS mutant metastatic colorectal cancer: results of the RASTRIC Phase I/II trial.

Sex Impacts Progression-Free Survival of Alectinib through Drug Exposure in Patients with ALK-Positive Non-Small Cell Lung Cancer.

Transfer of trastuzumab and pertuzumab into human breast milk: a case report.

Exposure-Response Relationships of Antibody Drug Conjugates in Solid Tumours.

Acute hemolytic anemia and methemoglobinemia in a pediatric oncology patient with G6PD deficiency: a case report.

Analytical Validation of an Annotation Tool for WGS-Based Pharmacogenomics: Preparing for Clinical Implementation in Pediatric Oncology.

Reducing the Burden of Interaction Studies in Cancer Patients Using a Stable Isotopically Labeled Microtracer: A Proof-of-Concept Study with Alectinib.

Semi-Physiological Population Pharmacokinetic Modeling of Oral and Intravenous Paracetamol to Quantify Presystemic Metabolism and Enterohepatic Recirculation.

Population Pharmacokinetics of Total and Protein-Unbound Prednisolone in Children with Immune-Mediated and Systemic Inflammatory Diseases.

An Overview of Liquid Chromatography-Mass Spectrometry (LC-MS) Methods for the Quantification of Antibody-Drug Conjugates.

Selpercatinib-induced renal tubular damage resulting in symptomatic hyponatremia and polyuria: a case report.

LC-MS/MS method development and validation for novel targeted anticancer therapies adagrasib, capmatinib, ensartinib, entrectinib, larotrectinib, lorlatinib, pralsetinib, selpercatinib and sotorasib.

Therapeutic Drug Monitoring of Oral Targeted Anticancer Drugs: Achievements, Experiences, Challenges, and the Path Forward.

Importance of Lysosomal Trapping and Plasmodium Parasite Infection on the Pharmacokinetics of Pyronaridine: A Physiologically Based Pharmacokinetic Model-Based Study.

Prolonged in-use physicochemical and biological stability of nivolumab and pembrolizumab diluted in saline infusion bags and in partially used medication vials.

Accidental tamoxifen ingestion in a two-year-old child without major immediate symptoms: Case report.

Measurement of Tralokinumab Concentrations in Serum and Tear Fluid of Atopic Dermatitis Patients and the Relationship With Treatment Response and Ocular Surface Disease.

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia-A comprehensive review.

Stabilization of Abiraterone in Human Plasma Using the Esterase Inhibitor Bis(4-nitrophenyl) Phosphate.

Implementing Pre-Emptive Pharmacogenetics: Impact of Early Pharmacogenetic Screening in a Pediatric Oncology Cohort of 1,151 Subjects.

Validated LC-MS/MS Method for Quantifying the Antiparasitic Nitroimidazole DNDI-0690 in Preclinical Target Site PK/PD Studies.

Quantitative analysis of DNDI-6174 using UPLC-MS/MS: A preclinical target site pharmacokinetic study.

Pharmacokinetic boosting of olaparib: Study protocol of a multicentre, open-label, randomised, non-inferiority trial (PROACTIVE-B).

Imatinib Desensitization After a Type IV Hypersensitivity Reaction in a Gastrointestinal Stromal Tumor Patient-A Case Report.

Improved survival with model-based dosing of antithymocyte globulin in pediatric hematopoietic cell transplantation.

Added prognostic value of circulating tumor cell numbers in CSF of patients with leptomeningeal metastasis from epithelial tumors.

Feasibility and efficacy of therapeutic drug monitoring of abiraterone in metastatic castration resistant prostate cancer patients.

Palbociclib exposure in relation to efficacy and toxicity in patients with advanced breast cancer.

The feasibility of using real world data as external control arms in oncology trials.

Evaluation of standard fludarabine dosing and corresponding exposures in infants and young children undergoing hematopoietic cell transplantation.

Treatment sequences and survival outcomes in advanced HR + HER2- breast cancer patients: a real-world cohort.

Pharmacokinetic exposure and treatment outcomes of lenvatinib in patients with renal cell carcinoma and differentiated thyroid carcinoma.

Development and validation of ultra-performance liquid chromatography tandem mass spectrometry methods for the quantitative analysis of the antiparasitic drug DNDI-6148 in human plasma and various mouse biomatrices.

A Population Pharmacokinetic Study to Evaluate Doxorubicin Exposure Across All Age Groups.

Therapeutic Drug Monitoring of Oral Oncology Drugs: Finding the Right Nails.

Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology - an analysis of the closed cohorts of a multicentre prospective study.

A joint model of longitudinal pharmacokinetic and time-to-event data to study exposure-response relationships: a proof-of-concept study with alectinib.

Effect of clofarabine and fludarabine exposure on outcome after pediatric allogeneic hematopoietic cell transplantation.

This site uses cookies